💪 Muscle Growth & PerformancePhase II

CJC-1295

Modified GRF 1-29 · GHRH Analog

A long-acting GHRH analog for sustained growth hormone release

Typical Dose

1–2 mg per week

Route

Subcutaneous

Frequency

Once or twice per week

Cycle

8–12 weeks

Overview

CJC-1295 is a modified version of a hormone your brain naturally uses to tell your pituitary gland to release growth hormone. The original version of this signal lasts only minutes in your body. CJC-1295 was engineered to last days by attaching to a blood protein called albumin, which acts like a slow-release carrier. The result is a steady, sustained increase in growth hormone over time, rather than a quick spike. It is almost always used together with Ipamorelin for a synergistic effect.

Key Benefits

Increases growth hormone and IGF-1 levels
Promotes lean muscle mass gain
Reduces body fat
Improves sleep quality and recovery
Enhances protein synthesis
Anti-aging effects

Mechanism of Action

CJC-1295 docks onto the GHRH receptor in your pituitary gland — the same receptor your brain's natural growth hormone signal uses. This tells the pituitary to produce and release growth hormone. What makes CJC-1295 different from the natural signal is its DAC modification, which lets it attach to albumin (a blood protein) and hitch a ride through your bloodstream for days instead of minutes. This keeps growth hormone levels elevated in a sustained, natural-feeling way rather than a sharp spike.

Dosing Protocol

Typical Dose

1–2 mg per week

Dose Range

1–2 mg/week

Frequency

Once or twice per week

Route

Subcutaneous injection

Cycle Length

8–12 weeks

CLINICAL NOTES

Almost always stacked with Ipamorelin for synergistic GH release. The combination provides a more natural, pulsatile GH release pattern.

Reconstitution calculator and cycle planner pre-filled with CJC-1295 defaults

Side Effects & Safety

Water retention
Tingling or numbness
Fatigue
Injection site reactions
Potential insulin resistance at high doses

IMPORTANT DISCLAIMER

This information is for educational purposes only. Always consult a qualified healthcare provider before starting any peptide protocol. Individual responses vary and medical supervision is recommended.

Research References

Common Stacks

CJC-1295 is almost always paired with a GHRP like Ipamorelin for synergistic GH release.

Frequently Asked Questions

Quick Reference

CategoryMuscle Growth & Performance
Research StatusPhase II
Typical Dose1–2 mg per week
RouteSubcutaneous
Cycle8–12 weeks

Community Reviews

Real experiences from the Peptide Insights community

Have experience with CJC-1295?

Log in to share your experience and help the community.

Log In to Review

No reviews yet for CJC-1295

Be the first to share your experience.